重新审视中低危乳腺癌术后放疗角色:SUPREMO试验结果在现代多模式实践中的适用性
本文结合SUPREMO试验10年结果,讨论全乳切除术后单纯胸壁放疗在中低危乳腺癌中的作用。试验入组1600例,主要为pT1-2N1M0和pT3N0M0,10年总生存无显著获益;因方案修改、未行区域淋巴结照射及病理质控差异等,其结果对当代多模式治疗的适用性有限。
要点
- SUPREMO报告10年总生存无显著获益,但方案修改削弱了统计效能与外推性。
- 试验仅照射胸壁、未行区域淋巴结照射(含内乳),限制其与现代综合放疗证据的衔接。
- 病理质控差异、手术方式演变和系统治疗进步改变了风险谱,需谨慎解读结论。
核心结论
- SUPREMO有助于理解全乳切除术后胸壁放疗的历史作用,但其对当代多模式乳腺癌管理的相关性有限。
研究设计与样本
- SUPREMO试验入组1600例,主要为pT1-2N1M0和pT3N0M0乳腺癌患者,评估全乳切除术后单纯胸壁放疗。
主要发现
- SUPREMO报告10年总生存无显著获益。
- 试验经历样本量缩减、入组延长和入组标准放宽等重大方案修改,损害了统计效能与外推性。
- 试验对区域淋巴结照射(含内乳淋巴结覆盖)使用有限,限制其在现代区域淋巴结照射生存获益证据背景下的适用性。
- 病理质控差异、手术方式从改良根治术向更保守方式演变及系统治疗进步,从根本上改变了风险谱和治疗范式。
关键数值与推荐
- 试验主要纳入pT1-2N1M0和pT3N0M0患者。
- 试验限定为胸壁照射、未行区域淋巴结照射,且以较低端中危病变为主(包括许多淋巴结阴性或有限淋巴结受累患者)。
临床怎么用
- 解读SUPREMO结果时需结合其仅胸壁照射、未行区域淋巴结照射及方案修改等设计局限。
- 现代实践中应整合生物学驱动风险分层、当代手术与系统治疗标准及精确放疗定义。
- 未来试验需采用务实设计、稳健质控和加速入组,以避免对仍可能从全乳切除术后放疗获益的特定患者治疗不足。
局限性
- 方案修改导致统计效能与外推性受损。
- 未充分使用区域淋巴结照射(含内乳覆盖),限制与现代证据的衔接。
- 病理质控差异、手术方式演变和系统治疗进步改变风险谱,影响结果解释。
- 以较低端中危病变为主(含许多淋巴结阴性或有限淋巴结受累患者),削弱临床影响力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The recently published 10-year results of the SUPREMO trial offer valuable insights into the role of postmastectomy radiotherapy (PMRT) to the chest wall alone in low- to intermediate-risk breast cancer patients. However, the trial s design and evolving standards in surgery, radiation therapy (RT), and systemic therapy necessitate careful interpretation. Main findings. SUPREMO enrolled 1,600 patients, primarily with pT1-2N1M0 and pT3N0M0 disease, and reported no significant overall survival (OS) benefit at 10 years. Major protocol modifications-including reduced sample size, extended accrual, and broadened eligibility criteria-were required to ensure trial completion but compromised statistical power and generalizability. The trial s limited use of regional nodal irradiation (RNI), including internal mammary node (IMN) coverage, further limits its applicability in the context of modern evidence demonstrating clear survival benefits from comprehensive RNI. Moreover, pathology quality assurance discrepancies, evolving surgical practices (from modified radical mastectomy to more conservative approaches), and advances in systemic therapy have fundamentally altered risk profiles and treatment paradigms. CONCLUSION: While SUPREMO contributes to understanding PMRT's historical role, its relevance to contemporary multimodal breast cancer management is limited. The restriction to chest wall irradiation, omission of RNI, and the predominance oflower-end intermediate-risk disease(including many patients withnode-negative or limited nodal involvement) diminish its clinical impact. Future trials must integrate biology-driven risk stratification, contemporary surgical and systemic standards, and precise RT definitions, requiring pragmatic designs, robust QA, and accelerated accrual to remain relevant and avoid undertreatment in selected patients who may still benefit from PMRT.
引用
- Machiels M, Kaidar-Person O, Marta GN, et al. Reconsidering the role of PMRT in low to intermediate risk breast cancer: Applying results from previous standards of treatment in the current multimodal practice. Radiother Oncol. 2026. PMID: 41633436. doi:10.1016/j.radonc.2026.111416
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。